



RJP:cms 09/30/02 4616-64091 143988.doc

PATENT  
Attorney Reference Number 4616-64091/RJP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 09 2002

TECH CENTER 1800/2900

In re application of: Mark G. Kuzyk, et al.

Art Unit: 1645

Application No.: 09/677,374

Filed: September 15, 2000

For: VACCINES AND AGENTS FOR  
INDUCING IMMUNITY AGAINST  
RICKETTSIAL DISEASES, AND  
ASSOCIATED PREVENTATIVE  
THERAPY

Examiner: Iesha P. Fields

Date: September 30, 2002

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on September 30, 2002 as First Class Mail in an envelope addressed to: BOX NON-FEE AMENDMENT, COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

Attorney for Applicant

TRANSMITTAL LETTER

BOX NON-FEE AMENDMENT  
COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Enclosed is an Amendment and Response to Restriction Requirement for the above application. The fee has been calculated as shown below.

CLAIMS AS AMENDED					
For	No. after amendment	No. paid for previously	Present Extra	Rate	Fee
Total Claims	17	- 32*	= -0	\$9.00	\$ 0.00
Indep. Claims	5	- 12**	= -0	\$43.00	\$ 0.00
Mult. Dep. Claims Fee (if not previously paid)				\$145.00	
One-month Extension of Time				\$55.00	
Two-month Extension of Time				\$205.00	
Three-month Extension of Time				\$470.00	
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00

\* greater of twenty or number for which fee has been paid.


\*\* greater of three or number for which fee has been paid.

- ☒ No additional fee is required.
- ☒ It is believed that no fee is required to file the accompanying Amendment and Response to Restriction Requirement. If such a fee is required, the Commissioner is authorized to charge said fees to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

By

  
Richard J. Polley  
Registration No. 28,107

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Client  
Docketing



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor Application of: Mark G. Kuzyk, et al.

Art Unit: 1645

Application No. 09/677,374

Filed: September 15, 2000


For: VACCINES AND AGENTS FOR INDUCING  
IMMUNITY AGAINST RICKETTSIAL  
DISEASES, AND ASSOCIATED  
PREVENTATIVE THERAPY

Examiner: Iesha P. Fields

Date: September 30, 2002

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on September 20, 2002 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231

  
Attorney for Applicant

# 12/B  
JM  
10/10/02


COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

**AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT**

In response to the Office action of June 28, 2002, please amend the claims of the application as follows.

Cancel claims 1 to 32, without prejudice.

Add new claims 33 to 49:

  
33. An isolated nucleic acid fragment encoding a protein of approximately 17 kDa, wherein said protein is immunoreactive with anti- *P. salmonis* serum, and wherein said protein has an amino acid sequence of one of SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 6, encompassing amino acid substitutions, additions and deletions that do not alter one of the immunogenicity and the function of said protein.

34. The nucleic acid fragment of claim 33, comprising a contiguous sequence of SEQ ID Nos: 1, 3 or 5, or the full length complement thereof.

35. The nucleic acid fragment of claim 33 operatively linked to a promoter.